Correction: Electroencephalographic power spectrum changes in cerebral small vessel disease combined with cognitive dysfunction and its relationship with neutrophil/lymphocyte ratio and its clinical value—A pilot study - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Changes in Electroencephalographic Power Spectrum Associated with Cognitive Impairment in Cerebral Small Vessel Disease and Its Correlation with Neutrophil/Lymphocyte Ratio—A Preliminary Investigation

  • By

  • Xiaomin Guo

  • Zongwei Liu

  • Weishuai Yuan

  • Aiqin Wei

  • Guogang Luo

  • September 15, 2026

Share

Clinical Scorecard: Correction: Changes in Electroencephalographic Power Spectrum Associated with Cognitive Impairment in Cerebral Small Vessel Disease and Its Correlation with Neutrophil/Lymphocyte Ratio—A Preliminary Investigation

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Correction
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPatients or participants described in the source article.
Care SettingSpecify the type of neurology care setting.

Key Highlights

  • remove

Guideline-Based Recommendations

Diagnosis

  • I
  • n
  • c
  • l
  • u
  • d
  • e
  • a
  • n
  • y
  • r
  • e
  • l
  • e
  • v
  • a
  • n
  • t
  • d
  • i
  • a
  • g
  • n
  • o
  • s
  • t
  • i
  • c
  • g
  • u
  • i
  • d
  • e
  • l
  • i
  • n
  • e
  • s
  • .

Management

  • I
  • n
  • c
  • l
  • u
  • d
  • e
  • a
  • n
  • y
  • r
  • e
  • l
  • e
  • v
  • a
  • n
  • t
  • m
  • a
  • n
  • a
  • g
  • e
  • m
  • e
  • n
  • t
  • g
  • u
  • i
  • d
  • e
  • l
  • i
  • n
  • e
  • s
  • .

Monitoring & Follow-up

  • I
  • n
  • c
  • l
  • u
  • d
  • e
  • a
  • n
  • y
  • r
  • e
  • l
  • e
  • v
  • a
  • n
  • t
  • m
  • o
  • n
  • i
  • t
  • o
  • r
  • i
  • n
  • g
  • g
  • u
  • i
  • d
  • e
  • l
  • i
  • n
  • e
  • s
  • .

Risks

  • I
  • n
  • c
  • l
  • u
  • d
  • e
  • a
  • n
  • y
  • r
  • e
  • l
  • e
  • v
  • a
  • n
  • t
  • r
  • i
  • s
  • k
  • g
  • u
  • i
  • d
  • e
  • l
  • i
  • n
  • e
  • s
  • .

Patient & Prescribing Data

Patients with cerebral small vessel disease and cognitive impairment

No specific treatment insights provided

Clinical Best Practices

  • add

Related Resources & Content

Original Source(s)

Correction: Electroencephalographic power spectrum changes in cerebral small vessel disease combined with cognitive dysfunction and its relationship with neutrophil/lymphocyte ratio and its clinical value—A pilot study

  • by Xiaomin Guo, Zongwei Liu, Weishuai Yuan, Aiqin Wei, Guogang Luo

  • September 15, 2026

Related Content

FDA approves FET-PET agent for glioma

The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.

Correction: Perivascular diffusion and white matter free water improve identification of cognitive impairment in cerebral small vessel disease

Neuroprosthesis for paralysis enables simultaneous speech and body language

  • September 14, 2026